NEW YORK (360Dx) – T2 Biosystems announced on Tuesday that it has begun a public offering of 5.657 million shares of its common stock.
T2 Bio has not yet priced its shares. It said that it will grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.
Leerink Partners will act as joint book-running manager for the offering, while Canaccord Genuity will act as passive book-running manager. In addition, Janney Montgomery Scott, JonesTrading Services, and WBB Securities will act as co-managers for the offering.